drugset
drugset / Trial / NCT05467722

Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543

NCT05467722 ↗

Phase 1 Completed 21 enrolled Concert Pharmaceuticals
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This is an open-label, single-dose, single-period, parallel group designed study to determine the effect of mild and moderate hepatic impairment on the pharmacokinetics (PK) of CTP-543 and its major metabolites following administration of a single 12 mg oral dose of CTP-543.

Timeline

Start
2022-06-01
Primary completion
2022-09-15
Completion
2022-09-21

Drugs

EvaluationDrugModalityDoseRoute
Subject CTP-543 Unknown 12 mg Oral

Indications

No indication recorded.